title: Structure activity relationships in alkylammonium C12-gemini surfactants used as dermal permeation enhancers.
abstract: The purpose of this study was to determine the ability and the safety of a series of alkylammonium C12-gemini surfactants to act as permeation enhancers for three model drugs, namely lidocaine HCl, caffeine, and ketoprofen. In vitro permeation studies across dermatomed porcine skin were performed over 24 h, after pretreating the skin for 1 h with an enhancer solution 0.16 M dissolved in propylene glycol. The highest enhancement ratio (enhancement ratio (ER)=5.1) was obtained using G12-6-12, resulting in a cumulative amount of permeated lidocaine HCl of 156.5 μg cm−2. The studies with caffeine and ketoprofen revealed that the most effective gemini surfactant was the one with the shorter spacer, G12-2-12. The use of the latter resulted in an ER of 2.4 and 2.2 in the passive permeation of caffeine and ketoprofen, respectively. However, Azone was found to be the most effective permeation enhancer for ketoprofen, attaining a total of 138.4 μg cm−2 permeated, 2.7-fold over controls. This work demonstrates that gemini surfactants are effective in terms of increasing the permeation of drugs, especially in the case of hydrophilic ionized compounds, that do not easily cross the stratum corneum. Skin integrity evaluation studies did not indicate the existence of relevant changes in the skin structure after the use of the permeation enhancers, while the cytotoxicity studies allowed establishing a relative cytotoxicity profile including this class of compounds, single chain surfactants, and Azone. A dependence of the toxicity to HEK and to HDF cell lines on the spacer length of the various gemini molecules was found.
authors: Sérgio M C
authors: SM
authors: Silva
authors: João J S
authors: JJ
authors: Sousa
authors: Eduardo F
authors: EF
authors: Marques
authors: Alberto A C C
authors: AA
authors: Pais
authors: Bozena B
authors: BB
authors: Michniak-Kohn
mesh_terms: D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*; D004357:Drug Synergism; D009924:Organ Culture Techniques; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism*; D012869:Skin Absorption / Q000187:drug effects / Q000502:physiology*; D013329:Structure-Activity Relationship; D013501:Surface-Active Agents / Q000737:chemistry* / Q000378:metabolism*; D013552:Swine
chemical_list: D001565:Benzoates; D000644:Quaternary Ammonium Compounds; D013501:Surface-Active Agents; C079524:Osmaron B
references: J Appl Toxicol. 1999 May-Jun;19(3):163-5
references: 10362266
references: Pharm Sci Technol Today. 2000 Sep 1;3(9):318-326
references: 10996573
references: J Phys Chem B. 2007 May 3;111(17):4401-10
references: 17425360
references: J Burn Care Rehabil. 1996 Nov-Dec;17(6 Pt 1):565-70
references: 8951547
references: Pharm Res. 1989 Sep;6(9):798-803
references: 2813277
references: Br J Dermatol. 1994 Jan;130(1):24-8
references: 7508256
references: Adv Colloid Interface Sci. 2002 Mar 29;97(1-3):205-53
references: 12027021
references: Int J Cosmet Sci. 1993 Dec;15(6):260-71
references: 19281616
references: J Invest Dermatol. 1989 Dec;93(6):774-9
references: 2584743
references: J Invest Dermatol. 2003 Aug;121(2):231-41
references: 12880413
references: Eur J Pharm Biopharm. 2012 Apr;80(3):663-73
references: 22137964
references: Eur J Pharm Biopharm. 1998 Jul;46(1):1-13
references: 9700018
references: Life Sci. 1994;55(7):533-40
references: 8041231
references: Contact Dermatitis. 1995 Oct;33(4):217-25
references: 8654070
references: Pharm Res. 2005 Nov;22(11):1918-25
references: 16132348
references: J Pharm Sci. 1999 Oct;88(10):955-8
references: 10514338
references: Int J Pharm. 1999 Mar 1;179(1):21-5
references: 10053198
references: Int J Pharm. 2001 Mar 14;215(1-2):229-40
references: 11250108
references: J Pharm Sci. 1988 Sep;77(9):776-8
references: 3225773
references: Pharm Sci Technol Today. 2000 Jan;3(1):36-41
references: 10637599
references: Phys Chem Chem Phys. 2010 Nov 21;12(43):14462-76
references: 20890505
references: J Pharm Pharmacol. 1985 Aug;37(8):578-80
references: 2864423
references: Chem Pharm Bull (Tokyo). 2000 Nov;48(11):1698-701
references: 11086898
references: Pharm Res. 2002 May;19(5):669-75
references: 12069171
references: Pharm Res. 2003 Oct;20(10):1612-8
references: 14620516
references: Mol Interv. 2004 Dec;4(6):308-12
references: 15616157
references: Angew Chem Int Ed Engl. 2000 Jun 2;39(11):1906-1920
references: 10940980
references: Int J Pharm. 2000 Jul 20;202(1-2):133-40
references: 10915936
references: J Colloid Interface Sci. 2002 Apr 15;248(2):203-20
references: 16290524
references: J Am Chem Soc. 2001 Feb 7;123(5):875-85
references: 11456621